'A European Medicines Agency committee on Friday recommended that Leqembi should be denied a marketing authorisation in the EU, severely knocking the likelihood of approval for use in the 27-member bloc. The neurodegenerative condition affects about 50mn people worldwide.'

https://www.ft.com/content/27eafb84-f8b0-428a-a275-f38e66ef8961